What is the current stock price of Insmed Incorporated (INSM)?

As of the latest market data, Insmed Incorporated (INSM) is trading at $106.40. The stock has seen a loss of -2.27% today.

Does Insmed Incorporated (INSM) pay a dividend?

Based on current data, Insmed Incorporated does not have a confirmed active dividend policy.

What is the market cap of Insmed Incorporated?

The current market capitalization of Insmed Incorporated (INSM) is approximately unavailable.

INSM

Insmed Incorporated·Healthcare

106.40

2.269%(−2.47)

Close Price

113.79

6.945%(+7.39)

Pre-Market

Last Updated: — ET

52W L: $65.5652W H: $212.75

INSM NEWS

prnewswire.com

21h ago

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m.

seekingalpha.com

May 20

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

marketbeat.com

May 18

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed NASDAQ: INSM Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company's latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended to provide “anchor points” around what he described as “one of the strongest launches in recent years.

seekingalpha.com

May 12

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

zacks.com

May 8

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.

seekingalpha.com

May 7

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

Company Profile

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Sector

Healthcare

Industry

Biotechnology

Employees

1,271

IPO Date

2000-06-01

Beta

0.89

Websitewww.insmed.com↗